275 related articles for article (PubMed ID: 35852863)
1. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
[TBL] [Abstract][Full Text] [Related]
2. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
[TBL] [Abstract][Full Text] [Related]
3. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
4. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
6. Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma.
Li N; Ho M
Methods Mol Biol; 2022; 2446():451-468. PubMed ID: 35157288
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
8. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
9. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
[TBL] [Abstract][Full Text] [Related]
10. Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
Sun M; Cao Y; Okada R; Reyes-González JM; Stack HG; Qin H; Li N; Seibert C; Kelly MC; Ruppin E; Ho M; Thiele CJ; Nguyen R
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631162
[TBL] [Abstract][Full Text] [Related]
11. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
13. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
14. Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells.
Halliwell E; Vitali A; Muller H; Alonso-Ferrero M; Barisa M; Gavriil A; Piapi A; Leboreiro-Babe C; Gileadi T; Yeung J; Pataillot-Meakin T; Fisher J; Tucker L; Donovan L; Chesler L; Chester K; Anderson J
Cytotherapy; 2023 Jan; 25(1):46-58. PubMed ID: 36396552
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
16. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.
Li N; Spetz MR; Li D; Ho M
Pharmacol Ther; 2021 Jul; 223():107892. PubMed ID: 33992682
[TBL] [Abstract][Full Text] [Related]
18. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
19. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
20. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
